Advertisement

Opiates as Immunosuppressive and Genotoxic Agents

  • Arthur Falek
  • Robert M. Donahoe
  • John J. Madden
  • David A. Shafer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 288)

Abstract

From a historical prospective our immunologic investigations started as a natural consequence of our findings that opiates reduced the genetic integrity of human lymphocytes indicated by evidence of an increased frequency of chromosome damage and a deficiency in DNA repair capacity. Such changes in genetic structure and function are expected to indicate mutagenic and/or carcinogenic outcomes (1).

Keywords

Acquire Immune Deficiency Syndrome Sister Chromatid Exchange Opiate Receptor Chromosome Damage Sulphur Mustard 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. Falek, J. J. Madden, D. A. Shafer, and R. M. Donahoe, Opiates as modulators of genetic damage and immunocompetence, Adv. Alcohol Subst. Abuse1:5 (1982).CrossRefGoogle Scholar
  2. 2.
    A. Falek, R. B. Jordan, B. S. King, P. J. Arnold, and W. D. Skelton, Human chromosomes and opiates, Arch. Gen. Psychiatry 27:511 (1972).PubMedCrossRefGoogle Scholar
  3. 3.
    A. Falek and I. J. Mcfadden, Cytogenetic follow-up of patients in a methadone maintenance program, a pilot study, in: “Fifth National Conference on Methadone Treatment,” R. L. Dupont and R. S. Freeman, eds., Nat. Assoc. Prev. Addict. Nar., New York (1973).Google Scholar
  4. 4.
    A. Falek and F. Hollingsworth, Heroin and chromosome damage, Arch. Gen. Psychiatry 37:227 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    D. Scott and F. Zampetti-Bosseler, Relationship between chromosome damage, cell cycle delay and cell killing induced by bleomycin or X-rays, Mutation Res. 151:83 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    C. Tanzarella, R. Desalvia, F. Degrassie, F. Palitti, H. C. Anderson, K. Hanson, and B. A. Kihlman, Effect of post treatments with caffeine during G2 on the frequencies of chromosome type aberrations produced by X-rays in human lymphocytes during G0 and Gl, Mutagenesis 1:41 (1986).PubMedCrossRefGoogle Scholar
  7. 7.
    D. A. Shafer, Replication bypass model of sister chromatid exchanges and implications for Bloom’s syndrome and Fanconi’s anemia, Human Genetics39:177 (1977).PubMedCrossRefGoogle Scholar
  8. 8.
    D. A. Shafer, Alternate replication bypass mechanisms for sister chromatid exchange formation, in: Sister Chromatid Exchanges, Progress and Topics in Cytogenetics 2:67 (1982).Google Scholar
  9. 9.
    D. A. Shafer, Replication bypass SCE mechanisms and the induction of single strand adducts or lesions of DNA in: “Sister Chromatid Exchanges: 25 years of Experimental Research,” A. Hollaender and R. Tice, eds., Plenum Press, New York (1984).Google Scholar
  10. 10.
    D. A. Shafer, A. Falek, J. J. Madden, F. Tadayon, M. Pline, P. J. Bokos, J. C. Kuehnle, and J. Mendelson, Parallel increases in SCE at base level and with UV treatment in human opiate users, Mutation Res. 109:73 (1983).PubMedCrossRefGoogle Scholar
  11. 11.
    H. K. Fischman, L. Roizin, E. Moralishvili, C. Joy, and J. D. Rainer, Effects of prolonged administration of “street heroin” on the chromosomes of Mucaca mulatta (rhesus) monkeys, in: “Neurotoxicology,” L. Roizin, H. Shiraki, and N. Grecevic, eds., Raven Press, New York, (1977).Google Scholar
  12. 12.
    H. K. Fischman, L. Roizin, E. Moralishvili, P. Albre, D. Ross, and J. D. Rainer, Blastogenic effects of heroin in pregnant monkeys and their offspring, Mutation Res. 118:77 (1983).PubMedCrossRefGoogle Scholar
  13. 13.
    D. G. Harnden and A. M. R. Taylor, Chromosomes and neoplasia, Adv. Hum. Genet. 9:1 (1979).PubMedGoogle Scholar
  14. 14.
    R. J. Wapner, J. Fitzsimmons, R. D. Ross, M. E. Rudrauff, A. B. Kurtz, and L. P. Finnegan, A quantitative evaluation of fetal growth failure in a drug abusing population, in: “NIDA Res. Mong. 34 Problem of Drug Dependence, 1980,” L. Harris, ed., Rockville, (1981).Google Scholar
  15. 15.
    J. D. Sapira, J. C. Ball, and H. Penn, Causes of death among institutionalized narcotic addicts, J. Chronic Dis. 22:733 (1970).PubMedCrossRefGoogle Scholar
  16. 16.
    P. D. Harris and R. Garret, Susceptibility of addicts to infection and neoplasia, New Engl. J. Med. 287:310 (1972).PubMedGoogle Scholar
  17. 17.
    J. Kmet, Opium and oesophageal cancer in Iran, Lancet II:999 (1973).Google Scholar
  18. 18.
    T. F. Hewer, E. Rose, P. Ghadiriank, M. Castegnoro, C. Malaveille, H. Bartsch, and N. Day, Ingested mutagens from opium and tobacco pyrolysis products and cancer of the oesophagus, Lancet II:494 (1978).CrossRefGoogle Scholar
  19. 19.
    A. Sadeghi, S. Behmard, and S. D. Vesselinovitch, Opium: a potential urinary bladder carcinogen in man, Cancer 43:2315 (1979).PubMedCrossRefGoogle Scholar
  20. 20.
    P. E. Perry, E. J. Thomson, Vjaijalami, H. J. Evans, N. E. Day, and H. Bartsch, Introduction of SCE by opium pyrolysates in CHO cells and human peripheral blood lymphocytes, Carcinogenesis 4:227 (1983).PubMedCrossRefGoogle Scholar
  21. 21.
    M. M. Lee and H. H. Loh, A study of DNA binding of narcotic analgesics, Biochem. Pharm. 24:1249 (1975).PubMedCrossRefGoogle Scholar
  22. 22.
    D. Brusick, An evaluation of the genetic effect of heroin (part A), pp. 1–44, National Institute on Drug Abuse Technical Report. Rockville, Md., (1978).Google Scholar
  23. 23.
    J. J. Madden, A. Falek, D. A. Shafer, and J. H. Glick, Effects of opiates and demographic factors on DNA repair synthesis in human leukocytes, Proc. Nat. Acad. Sci. 76:5769 (1979).PubMedCrossRefGoogle Scholar
  24. 24.
    C. Atchard, H. Benard, and C. Gagneux, Action de la morphine sur proprietes leukococytairei, leuka-diagnastic du morphinisms, Bull. Mem. Soc. Med. Hosp. Paris 28:958 (1909).Google Scholar
  25. 25.
    C. E. Terry and M. Pellens, The Opium Problem. Bureau of Social Hygiene, New York (1928).Google Scholar
  26. 26.
    W. E. Dismukes, A. W. Karchmer, R. F. Johnson, and W. J. Dougherty, Viral hepatitis associated with illicit parenteral use of drugs, JAMA 206:1048 (1968).PubMedCrossRefGoogle Scholar
  27. 27.
    J. D. Sapira, The narcotic addict as a medical patient, Amer. J. Med. 45:555 (1968).PubMedCrossRefGoogle Scholar
  28. 28.
    P. D. Harris and R. Garret, Susceptibility of addicts to infection and neoplasia, N. England J. Med. 287:310, (1972).Google Scholar
  29. 29.
    D. B. Louria, Infectious complications of non alcoholic drug abuse, Ann. Rev. Med. 25:219 (1974).PubMedCrossRefGoogle Scholar
  30. 30.
    R. C. Gallo, S. Z. Salahuddin, M. Popovic, G. M. Shearen, M. Kaplan, B. F. Haynes, T. J. Polker, R. Redfield, J. Oleske, and B. Safai, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS, Science 234:500 (1984).CrossRefGoogle Scholar
  31. 31.
    R. M. Selik, H. W. Haverkos, and J. W. Curran, Acquired immune deficiency syndrome (AIDS) in the United States, 1978–1982, Am. J. Med. 76:493 (1984).PubMedCrossRefGoogle Scholar
  32. 32.
    S. W. Brown, B. Stimmel, R. N. Taub, S. Kochwa, and R. E. Rosenfield, Immunologic dysfunction in heroin addicts, Arch. Int. Med. 134:1001 (1974).CrossRefGoogle Scholar
  33. 33.
    A. Lopker, L. G. Abood, W. Hoss, and F. J. Lionetti, Stereoselective muscarinic acetylcholine and opiate receptors in human phagocytic leukocytes, Biochem. Pharmacol. 29:1361 (1980).PubMedCrossRefGoogle Scholar
  34. 34.
    J. Wybran, T. Appelboom, J.-P. Famaey, and A. Govaerts, Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human T-lymphocytes, J. Immunol. 123:1068 (1979).PubMedGoogle Scholar
  35. 35.
    S. C. Gilman, J. M. Schwartz, R. J. Milner, F. E. Bloom, and J. D. Feldman, B-Endorphine enhances lymphocyte proliferative responses, Proc. Natl. Acad. Sci. USA 79:4226 (1982).PubMedCrossRefGoogle Scholar
  36. 36.
    P. M. Mathews, Enhancement of natural cytotoxicity by B-endorphin, I. Immunol. 130:1658 (1983).Google Scholar
  37. 37.
    Y. Shavit, Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity, Science 223:188 (1984).PubMedCrossRefGoogle Scholar
  38. 38.
    D. E. Van Epps and L. Saland, B-Endorphin and met-enkephalin stimulate human peripheral blood mononuclear cell chemotoxis, J. Immunol. 132:3046 (1984).PubMedGoogle Scholar
  39. 39.
    G. C. Miller, A. J. Murgo, and N. P. Plotnikoff, Enkephalin-enhancement of active T-cell rosettes from lymphoma patients, Clin. Immunol. Immuno-pathol. 26:446 (1983).CrossRefGoogle Scholar
  40. 40.
    R. J. McDonough, J. J. Madden, A. Falek, D. A. Shafer, M. Pline, D. Gordon, P. Bokos, J. C. Kuehnle, and J. Mendelson, Alterations of T-and null lymphocyte frequencies in the peripheral blood of human opiate addicts: In vivo evidence for opiate receptor sites on T-lymphocytes, J. Immunol. 125:2539 (1980).PubMedGoogle Scholar
  41. 41.
    R. J. McDonough, J. J. Madden, H. S. Rosman, A. Falek, N. K. Wenger, D. A Shafer, P. J. Bokos, J. C. Kuehnle, and J. Mendelson, Opiate inhibition of sheep erythrocyte binding to T-lymphocytes: reversal by naloxone and cyclic nucleotides, Problems of Drug Dependence. NIDA Research Monogr. 34:159 (1981).Google Scholar
  42. 42.
    A. Bernard, C. Gelin, B. Raynal, D. Pham, C. Gossen, and L. Boumsell, Phenomenon of human T-cell rosetting with sheep erythrocytes analyzed with monoclonal antibodies. Modulation of a partially hidden epitope determining the conditions of interaction between T-cells and erythrocytes, J. Exp. Med. 155:1317 (1982).PubMedCrossRefGoogle Scholar
  43. 43.
    G. M Edelman, Surface modulation in cell recognition and cell growth, Science192:218 (1976).PubMedCrossRefGoogle Scholar
  44. 44.
    J. Schlessinger, Y. Shechter, M. C. Willingham, and I. Pastan, Direct visualization of binding aggregation and internalization of insulin and epidermal growth factor on living fibroblast cells, Proc. Natl. Acad. Sci. USA 75:2659 (1978).PubMedCrossRefGoogle Scholar
  45. 45.
    E. Loumeye and K. J. Catt, Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells, Science 215:983 (1982).CrossRefGoogle Scholar
  46. 46.
    R. S. Mittler, P. E. Rao, M. A. Talle, R. Look, and G. Goldstein, Cell membrane perturbation of resting T-cells and thymocytes causes display of activation antigens, J. Exp. Med. 158:99 (1983).PubMedCrossRefGoogle Scholar
  47. 47.
    R. M. Donahoe, J. J. Madden, F. Hollingsworth, D. A. Shafer, and A. Falek, Morphine depression of T-cell E-rosetting. Definition of the process, Fed. Proc. Am. Soc. Exp. BioL 44:95 (1985).Google Scholar
  48. 48.
    R. M. Donahoe, C. E. Buesos-Ramos, F. Donahoe, J. J. Madden, A. Falek, J. K. A. Nicholson, and P. Bokos, Mechanistic implications of the findings that opiates and other drugs of abuse moderate T-cell surface receptors and antigenic markers, Ann. New York Acad. Sci. 496:711 (1987).CrossRefGoogle Scholar
  49. 49.
    J. J. Madden, R. M. Donahoe, I. E. Smith, D. E. Martinson, S. Moss-Wells, L. Klein, and A. Falek, Increased rate of E rosette formation by T-lymphocytes of pregnant women who drink alcohol, Clin. Immunol. Immunopathol. 33:67 (1984).PubMedCrossRefGoogle Scholar
  50. 50.
    R. M. Donahoe, J. J. Madden, F. Hollingsworth, D. A. Shafer, A. Falek, J. K. A. Nicholson, and P. Bokos, Immunomodulation by behaviorally active drugs provides a paradigm for connecting AIDS like processes and psycho-neuroimmunology, in: “Neuroimmunomodulation, Proceeding of the First International Workshop on Neuroimmunomodulation,” N. H. Spector, ed., International Working Group on Neuroimmunomodulation, Bethesda, (1985).Google Scholar
  51. 51.
    R. M. Donahoe, C. E. Buesos-Ramos, F. Donahoe, J. J. Madden, A. Falek, J. K. A. Nicholson, and P. Bokos, Coordinate and independent effects of heroin, cocaine and alcohol abuse on T-cell E-rosette formation and antigenic marker expression, Clin. Immunol. Immunopathol 41:254 (1986).PubMedCrossRefGoogle Scholar
  52. 52.
    P. Cushman and R. Kharana, Marijuana and T-lymphocyte rosettes, Clin. Pharmacol. Ther. 19:310 (1976).PubMedGoogle Scholar
  53. 53.
    W. Shain and D. O. Carpenter, Mechanisms of synaptic modulation, Int. Rev. Neurobiol. 22:205 (1981).PubMedCrossRefGoogle Scholar
  54. 54.
    J. M. Hiller, L. M. Angel, and E. J. Simon, Multiple opiate receptors:Alcohol selectivity inhibits binding to delta receptors, Science 214:468 (1981).PubMedCrossRefGoogle Scholar
  55. 55.
    M. E. Charness, A. S. Gordon, and I. Diamond, Ethanol modulation of opiate receptors in cultured neural cells, Science 222:1246 (1983).PubMedCrossRefGoogle Scholar
  56. 56.
    J. N. Sheagren and C. C. Tuazon, Immunological aspects, in: “Drug Abuse:Cli-nical and Basic Aspects” S. N. Pradhen and S. N. Duttu, eds., Mosby, St. Louis, (1977).Google Scholar
  57. 57.
    A. G. Dalgleish, P. C. L. Beverley, P. R. Clapham, D. H. Crawford, M. F. Greaves, and R. A. Weiss,The CDA (T4) antigenisan essential component of the receptor for the AIDS retrovirus, Nature (London) 312:763 (1984).PubMedCrossRefGoogle Scholar
  58. 58.
    D. Klatzmann, E. Champagne, S. Chamaret, J. Greust, D. Guetard, T. Hircend, J.-C. Gluckman, and L. Montagnier, T-lymphocyte T-4 molecule behaves as a receptor for human retrovirus LAV, Nature (London) 312:767 (1984).PubMedCrossRefGoogle Scholar
  59. 59.
    D. C. Des Jarlais, S. R. Freedman, and W. Hopkins, Risk reduction for the acquired immunodeficiency disease syndrome among intravenous drug users, Ann. Intern. Med. 103:755 (1985).PubMedGoogle Scholar
  60. 60.
    J. Layon, A. Idris, M. Warzynski, R. Shere, D. Brauner, O. Patch, D. McCulley, and P. Orris, Altered T-lymphocyte subsets in hospitalized intravenous drug abusers, Arch. Intern. Med. 133:1376 (1984).CrossRefGoogle Scholar
  61. 61.
    R. H. Kermen and W. P. Geis, Total and active T-cell dynamics in renal allograph recipients, Surgery 79:398 (1983).Google Scholar
  62. 62.
    R. H. Kerman, M. Floyd, C. T. VanBuren, and B. D. Kahen, Improved allograph survival of strong immune responder-high risk recipients with adjuvant antithymocyte globulin therapy, Transplantation 30:450 (1980).PubMedCrossRefGoogle Scholar
  63. 63.
    D. C. Des Jarlais, Personal Communication.Google Scholar
  64. 64.
    R. M. Donahoe and A. Falek, Neuroimmunomodulation by opiates and other drugs of abuse. Relationship to HIV infection and AIDS, Psychological. Neuropsychiatric and Substance Abuse Aspects of AIDS, T.Peter Bridge, ed., Raven Press, New York (1988).Google Scholar
  65. 65.
    J. S. McDougal, M. S. Kennedy, J. M. Sligh, S. P. Cort, A. Mawle, and J. K. A. Nicholson, Binding of HTLV III/LAV to T4+-T cells by a complex of the 110K viral protein and the T-4 molecule, Science 231:382 (1986).PubMedCrossRefGoogle Scholar
  66. 66.
    J. N. Mehrishi and I. H. Mills, Opiate receptors on lymphocytes and platelets in man, Clin. Immunol. Immunopathol. 27:240 (1983).PubMedCrossRefGoogle Scholar
  67. 67.
    J. J. Madden, R. M. Donahoe, J. Zwemer-Collins, D. A. Shafer, and A. Falek, Binding of naloxone to human T-lymphocytes, Biochem. Pharmacol. 36:4103 (1987).PubMedCrossRefGoogle Scholar
  68. 68.
    W. L. Farrar, J. M. Hill, A. Harel-Bellan, M. Vinocour, The immune logical brain, Immunol. Rev. 100:361 (1987).PubMedCrossRefGoogle Scholar
  69. 69.
    J. J. Madden and A. Falek, The use of nonneuronal cells as in vitro model systems for studying the genetics of opiate abuse, Adv. Alcohol Subst. Abuse. (In press)Google Scholar
  70. 70.
    J. -L. Carpentier, P. Gordon, M. Amherdt, E. Van Obbergham, C. R. Kahn, and L. Orci, 125 I-insulin binding to cultured human lymphocytes. Initial localization and fate of hormone determined quantitative election microscope autoradiography, J. Clin. Invest. 62:1057 (1978).CrossRefGoogle Scholar
  71. 71.
    E. J. Simon, J. M. Hiller, and I. Edelman, Stereospecific binding of the potent narcotic analgesic (H) E-trophine to rat brain homogenate, Proc. Nat. Acad. Sci. 70:2243 (1973).CrossRefGoogle Scholar
  72. 72.
    A. Falek, J. J. Madden, R. M. Donahoe, and D. A. Shafer, Genetic and immunologic consequences of opiate actions on T-lymphocytes, in: “Genetic and Perinatal Effects of Abused Substances,” M. Braude and A. M. Zimmerman, eds., Academic Press, Orlando (1987).Google Scholar
  73. 73.
    D. A. Shafer, A. Falek, R. M. Donahoe, and J. J. Madden, Biogenetic effects of opiates, Int. J. Drug Abuse (In Press)Google Scholar
  74. 74.
    F. Ashal and T. T. Puck, Cytoskeletal involvement in cAMP-induced sensitization of chromatin to nuclease digestion in transformed Chinese hamster ovary KI cells, Proc. Nat. Acad. Sci. USA 81:5145 (1984).CrossRefGoogle Scholar
  75. 75.
    D. A. Shafer, G. S. Roubin, A. A. Raviele, and V. G. Dunbar, Enhanced assays reveal chromosome damage in cardiac staff conducting diagnostic radiological procedures, Mutation Res. (In press)Google Scholar
  76. 76.
    D. A. Shafer, V. G. Dunbar, A. Falek, R. M. Donahoe, J. J. Madden, and P. J. Bokos, Enhanced assays detect increased chromosome damage and sister chromatid exchanges in heroin addicts, Mutation Res. (In Press)Google Scholar
  77. 77.
    K. Hansson, A. T. Natarajan, B. A. Kihlman, Effect of caffeine in G2 on X-ray induced chromosome aberrations and mitotic inhibition in ataxia telangiectasia fibroblast and lymphoblastoid cells, Human Genet. 67:329 (1984).CrossRefGoogle Scholar
  78. 78.
    H. J. Fingert, J. D. Chang, and A. B. Pardee, Cytotoxic, cell cycle and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents, Cancer. Res. 46:2463 (1986).PubMedGoogle Scholar
  79. 79.
    K. Y. Jan, R. Y. Huang, and T. C. Lee, Different modes of action of sodium arsenite, 3 aminobenzamide and caffeine on the enhancement of methena-sulfonate clastogenicity, Cytogenet. Cell Genet. 41:202 (1986).PubMedCrossRefGoogle Scholar
  80. 80.
    J. J. Roberts, V. P. Kotsaki-Kovatsi, Potentiation of sulphur mustard or cisplatin-induced toxicity by caffeine in Chinese hamster cells correlates with formation of DNA double-strand breaks during replication on a damaged template, Mutation Res. 165:207–220 (1986).PubMedGoogle Scholar
  81. 81.
    K. F. Weibezahn and T. M. Coquerelle, Relationship between double strand break rejoining and G2 block formation in V79 cells, Radiat. Environ. Biophys. 25:13 (1986).PubMedCrossRefGoogle Scholar
  82. 82.
    I. Ceccherini, N. Loprieno, and I. Sbrana, Caffeine post-treatment causes a shift in chromosome aberration types induced by mytocin C suggesting a caffeine-sensitive mechanism of DNA repair in G2, Mutagenesis 3:39 (1988).PubMedCrossRefGoogle Scholar
  83. 83.
    L. Sabatier and B. Dutillaux, Effect of caffeine in Franconi anemia, Human Genet. 79:242 (1988).CrossRefGoogle Scholar
  84. 84.
    F. Palitti, F. Degrassi, T. C. Desalvia, M. Fiore, Potentiation of induced sister chromatid exchanges and chromatid type aberrations by inhibitors of DNA synthesis and repair in G2, in: “Sister Chromatid Exchanges:part A,” R. R. Tice and A. Hollaender, eds., Plenum, New York (1984).Google Scholar
  85. 85.
    R. Schlegel, and A. B. Pardee, Caffeine induced uncoupling of mitosis from the completion of DNA replication in mammalian cells, Science 232: 1264 (1986).PubMedCrossRefGoogle Scholar
  86. 86.
    S. Grinfeld, and P. Jacquet, G2 arrest in mouse zygotes after X-irradiation: reversion by caffeine and influence on chromosome abnormalities, Int. J. Rad. Biol. 54:257 (1988).PubMedCrossRefGoogle Scholar
  87. 87.
    R. Bases, F. Mendez, D. Liebeskin, F. Elequin, and S. Neubort, DNA of He La cells during caffeine-promoted recovery from X-ray induced G2 arrest, Int. J. Radiat. Biol. 37:437 (1980).CrossRefGoogle Scholar
  88. 88.
    J. Timson, Caffeine, Mutation Res. 47:1 (1977).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Arthur Falek
    • 1
  • Robert M. Donahoe
    • 1
    • 2
  • John J. Madden
    • 1
  • David A. Shafer
    • 1
  1. 1.Human and Behavior Genetics Laboratory, Department of PsychiatryEmory University GMHIAtlantaUSA
  2. 2.Psychoimmunology Laboratory, Department of PsychiatryEmory University GMHIAtlantaUSA

Personalised recommendations